Suppr超能文献

CXCL13/CXCR5 通过激活感觉神经元中的 p38MAPK 增强 Nav1.8 钠通道电流密度进而参与炎性疼痛。

CXCL13/CXCR5 enhances sodium channel Nav1.8 current density via p38 MAP kinase in primary sensory neurons following inflammatory pain.

机构信息

Pain Research Laboratory, Institute of Nautical Medicine, Jiangsu Key Laboratory of Inflammation and Molecular Drug Target, Nantong University, Nantong, Jiangsu 226019, China.

Department of Anesthesiology, The First People's Hospital of Yancheng, Jiangsu 224005, China.

出版信息

Sci Rep. 2016 Oct 6;6:34836. doi: 10.1038/srep34836.

Abstract

CXCL13 is a B lymphocyte chemoattractant and activates CXCR5 receptor in the immune system. Here we investigated whether CXCL13/CXCR5 mediates inflammatory pain in dorsal root ganglia (DRG) and the underlying mechanisms. Peripheral injection of complete Freund's Adjuvant (CFA) increased the expression of CXCL13 and CXCR5 in DRG neurons. In Cxcr5 mice, CFA-induced pain hypersensitivity were attenuated. Whole-cell patch-clamp recording showed that the excitability of dissociated DRG neurons was increased after CFA injection or CXCL13 incubation from wild-type (WT) mice, but not from Cxcr5 mice. Additionally, sodium channel Nav1.8 was co-expressed with CXCR5 in dissociated DRG neurons, and the increased neuronal excitability induced by CFA or CXCL13 was reduced by Nav1.8 blocker. Intrathecal injection of Nav1.8 blocker also attenuated intrathecal injection of CXCL13-induced pain hypersensitivity. Furthermore, CXCL13 increased Nav1.8 current density in DRG neurons, which was inhibited by p38 MAP kinase inhibitor. CFA and CXCL13 increased p38 phosphorylation in the DRG of WT mice but not Cxcr5 mice. Finally, intrathecal p38 inhibitor alleviated CXCL13-induced pain hypersensitivity. Taken together, these results demonstrated that CXCL13, upregulated by peripheral inflammation, acts on CXCR5 on DRG neurons and activates p38, which increases Nav1.8 current density and further contributes to the maintenance of inflammatory pain.

摘要

CXCL13 是一种 B 淋巴细胞趋化因子,可激活免疫系统中的 CXCR5 受体。在这里,我们研究了 CXCL13/CXCR5 是否在背根神经节 (DRG) 中介导炎症性疼痛及其潜在机制。完全弗氏佐剂 (CFA) 外周注射增加了 DRG 神经元中 CXCL13 和 CXCR5 的表达。在 Cxcr5 小鼠中,CFA 诱导的痛觉过敏减轻。全细胞膜片钳记录显示,CFA 注射或 CXCL13 孵育后,来自野生型 (WT) 小鼠而非 Cxcr5 小鼠的分离 DRG 神经元的兴奋性增加。此外,钠通道 Nav1.8 与分离的 DRG 神经元中的 CXCR5 共表达,并且 CFA 或 CXCL13 诱导的神经元兴奋性增加被 Nav1.8 阻滞剂减少。鞘内注射 Nav1.8 阻滞剂也减轻了鞘内注射 CXCL13 诱导的痛觉过敏。此外,CXCL13 增加了 DRG 神经元中 Nav1.8 电流密度,该密度被 p38 MAP 激酶抑制剂抑制。CFA 和 CXCL13 增加了 WT 小鼠而不是 Cxcr5 小鼠的 DRG 中 p38 的磷酸化。最后,鞘内 p38 抑制剂减轻了 CXCL13 诱导的痛觉过敏。总之,这些结果表明,外周炎症上调的 CXCL13 作用于 DRG 神经元上的 CXCR5,并激活 p38,增加 Nav1.8 电流密度,进一步有助于维持炎症性疼痛。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9162/5052602/3d89ce9cfab1/srep34836-f1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验